QR код

Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma

Abstract Coronavirus disease 2019 (COVID‐19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID‐19 hyperimmune globulin (COVID‐HIG), a passive immunotherapy, is prepared from the plasma of healthy donors vaccinated with BBIBP‐CorV (S...

Повний опис

Збережено в:
Автори: Ding Yu, Yu‐Feng Li, Hong Liang, Jun‐Zheng Wu, Yong Hu, Yan Peng, Tao‐Jing Li, Ji‐Feng Hou, Wei‐Jin Huang, Li‐Dong Guan, Ren Han, Yan‐Tao Xing, Yong Zhang, Jia Liu, Lu Feng, Chun‐Yan Li, Xiao‐Long Liang, Ya‐Ling Ding, Zhi‐Jun Zhou, De‐Ming Ji, Fei‐Fei Wang, Jian‐Hong Yu, Kun Deng, Dong‐Mei Xia, De‐Mei Dong, Heng‐Rui Hu, Ya‐Jie Liu, Dao‐Xing Fu, Yan‐Lin He, Dong‐Bo Zhou, Hui‐Chuan Yang, Rui Jia, Chang‐Wen Ke, Tao Du, Yong Xie, Rong Zhou, Ce‐Sheng Li, Man‐Li Wang, Xiao‐Ming Yang
Формат: Artigo
Мова:Inglês
Опубліковано: Wiley 2022-05-01
Серія:Advanced Science
Предмети:
COVID‐19 hyperimmune globulin
passive immunotherapy
SARS‐CoV‐2 variant
sinopharm COVID‐19 vaccine
Онлайн доступ:https://doi.org/10.1002/advs.202104333
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси